Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Jun;8(3):307-310.
doi: 10.21037/hbsn.2019.01.21.

Mortality from liver cirrhosis and HCC in the DAA era: success in viral control is darkened by raise of metabolic disease

Antonio Saviano  1   2 , Thomas F Baumert  1   2
Affiliations
Editorial

Mortality from liver cirrhosis and HCC in the DAA era: success in viral control is darkened by raise of metabolic disease

Antonio Saviano et al. Hepatobiliary Surg Nutr. 2019 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Age-standardized mortality rates for cirrhosis (A) and HCC (B) in United States between 2007 and 2016. HCV-related cirrhosis mortality significantly decreased after the introduction of DAAs while HCV-related HCC mortality did not increase. After the introduction of entecavir and tenofovir, mortality of HBV-cirrhosis significantly decreased and HBV-HCC mortality showed a decline trend. ALD and NAFLD mortality rates dramatically raised over the study period. Adapted from Kim et al. (9). ALD, alcoholic liver disease; DAA, direct antiviral agent; ETV, entecavir; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; NAFLD, non-alcoholic liver disease, TDF, tenofovir.
See this image and copyright information in PMC

Comment on

References

    1. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014;12:145. 10.1186/s12916-014-0145-y - DOI - PMC - PubMed
    1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-128. 10.1016/S0140-6736(12)61728-0 - DOI - PMC - PubMed
    1. Kanwal F, Kramer J, Asch SM, et al. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology 2017;153:996-1005.e1. 10.1053/j.gastro.2017.06.012 - DOI - PubMed
    1. van der Meer AJ, Feld JJ, Hofer H, et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. J Hepatol 2017;66:485-93. 10.1016/j.jhep.2016.10.017 - DOI - PubMed
    1. Llovet JM, Villanueva A. Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. Nat Rev Gastroenterol Hepatol 2016;13:561-2. 10.1038/nrgastro.2016.140 - DOI - PubMed